Determining Targets for Antiretroviral Drug Concentrations: A Causal Framework Illustrated With Pediatric Efavirenz Data From the <scp>CHAPAS</scp>‐3 Trial
Our analyses demonstrate that a causal approach may lead to different minimum concentration limits than analyses that are based on purely predictive models. Moreover, the approach highlights that indirect causes of failure, such as patients' metabolizing status, may predict patients' failure risk, but do not alter the threshold at which antiviral activity of efavirenz is severely reduced.
Authors
- David Marinus Burger (ORCID: https://orcid.org/0000-0001-7279-2818)
- Helen McIlleron (ORCID: https://orcid.org/0000-0002-0982-6226)
- Diana M. Gibb (ORCID: https://orcid.org/0000-0002-9738-5490)
- Paolo Denti (ORCID: https://orcid.org/0000-0001-7494-079X)
- Michael Schomaker (ORCID: https://orcid.org/0000-0002-8475-0591)
- Iván Díaz (ORCID: https://orcid.org/0000-0001-9056-2047)
- Andrzej Bienczak
- Ann Sarah Walker
Institutions
- Novartis (Switzerland) (CH)
- Radboud University Nijmegen (NL)
- University of Cape Town (ZA)
- Radboud University Medical Center (NL)
- MRC Clinical Trials Unit at UCL (GB)
- UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik (AT)
- Wellcome Centre for Infectious Diseases Research in Africa (ZA)
- University College London (GB)
- New York University (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/pds.70051
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- National Institute for Health and Care Research
- Deutsche Forschungsgemeinschaft
- Department for International Development
- Medical Research Council
- European and Developing Countries Clinical Trials Partnership